Maxim Group restated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report sent to investors on Thursday morning. They currently have a $8.00 price objective on the biotechnology company’s stock.
“Viking reported 4Q17 with a net loss of $4.1M and ended the period with $20.6M in cash excluding the $63M capital raise in February. Based on our estimate of $23M-$25M per year in operating expenses, Viking has runway into mid-2020. We believe the strong cash position strengthens possible deal terms with a partner for the pivotal trial.”,” Maxim Group’s analyst wrote.
Several other research analysts have also recently weighed in on VKTX. Roth Capital set a $6.00 price objective on shares of Viking Therapeutics and gave the company a buy rating in a report on Wednesday, November 29th. BidaskClub cut shares of Viking Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, February 15th. ValuEngine cut shares of Viking Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Finally, HC Wainwright reissued a buy rating and set a $7.00 price objective on shares of Viking Therapeutics in a report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $7.67.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. analysts predict that Viking Therapeutics will post -0.63 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in Viking Therapeutics during the third quarter valued at approximately $108,000. Creative Planning grew its position in Viking Therapeutics by 600.0% during the fourth quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 60,000 shares during the period. Cornerstone Capital Inc. bought a new stake in Viking Therapeutics during the fourth quarter valued at approximately $352,000. Geode Capital Management LLC grew its position in Viking Therapeutics by 276.2% during the fourth quarter. Geode Capital Management LLC now owns 117,619 shares of the biotechnology company’s stock valued at $477,000 after buying an additional 86,355 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in Viking Therapeutics during the third quarter valued at approximately $554,000. Institutional investors own 19.71% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.